Biomaterial Database

HTLV-II subtype b among injecting drug users in Spain. 1994

A Vallejo, and A García-Sáiz

UI	MeSH Term	Description	Entries
D008297	Male		Males
D005260	Female		Females
D006800	Deltaretrovirus Infections	Infections caused by the HTLV or BLV deltaretroviruses. They include human T-cell leukemia-lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED).	BLV Infections,HTLV Infections,HTLV-BLV Infections,BLV Infection,Deltaretrovirus Infection,HTLV BLV Infections,HTLV Infection,HTLV-BLV Infection,Infection, Deltaretrovirus,Infections, Deltaretrovirus
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D013030	Spain	Country located between France on the northeast and Portugal on the west and bordered by the Atlantic Ocean and the Mediterranean Sea. The capital is Madrid.	Balearic Islands,Canary Islands
D015367	Human T-lymphotropic virus 2	A strain of PRIMATE T-LYMPHOTROPIC VIRUS 2 that can transform normal T-lymphocytes and can replicate in both T- and B-cell lines. The virus is related to but distinct from HTLV-1.	HTLV-2,HTLV-II,Human T-Cell Leukemia Virus II,Human T-Lymphotropic Virus II,Leukemia Virus II, Human T-Cell,T-Cell Leukemia Virus II, Human,Human T Cell Leukemia Virus II,Human T Lymphotropic Virus II,Leukemia Virus II, Human T Cell,T Cell Leukemia Virus II, Human,Human T lymphotropic virus 2
D015497	HIV-1	The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.	Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015528	HIV Seroprevalence	Studies of the number of cases where human immunodeficiency virus (HIV) is present in a specific population at a designated time. The presence in a given individual is determined by the finding of HIV antibodies in the serum (HIV SEROPOSITIVITY).	Seroprevalence, HIV
D015819	Substance Abuse, Intravenous	Abuse, overuse, or misuse of a substance by its injection into a vein.	Drug Abuse, Intravenous,Drug Abuse, Parenteral,Intravenous Drug Abuse,Intravenous Substance Abuse,Parenteral Drug Abuse

Related Publications

A Vallejo, and A García-Sáiz

HTLV-II among injecting drug users in Stockholm.

January 1994, Scandinavian journal of infectious diseases,

A Vallejo, and A García-Sáiz

HTLV-2b among HIV type 1-coinfected injecting drug users in Spain.

May 2011, AIDS research and human retroviruses,

A Vallejo, and A García-Sáiz

Associations among HTLV-I, HTLV-II, and HIV in injecting drug users in Salvador, Brazil.

June 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,

A Vallejo, and A García-Sáiz

Recent spread of human T lymphotropic virus type II among injecting drug users in Spain. HTLV Spanish Study Group.

October 1996, The Journal of infectious diseases,

A Vallejo, and A García-Sáiz

Absence of markers for HTLV infection among australian injecting drug users.

July 1992, The Medical journal of Australia,

A Vallejo, and A García-Sáiz

Low prevalence of HTLV-I/II infection among HIV-1-infected injecting drug users in Russia.

August 1999, Journal of acquired immune deficiency syndromes (1999),

A Vallejo, and A García-Sáiz

Hepatitis B vaccine uptake among injecting drug users.

March 2004, Journal of public health (Oxford, England),